DOWNLOADS
Downloads
Explore our research and technology
in greater depth.
Our public materials explain the scientific background, technology concepts, and research history behind Biozipcode, Inc.’s R&D in more detail than a website page can.
Our work centers on research into “diabetes stem cells” (DSCs), a proposed research term and Biozipcode™ cell-targeting technology, with applications under study in diabetes, biomarkers, DDS, cancer, tissue regeneration, and other areas.
Alongside company and technology overview PDFs, this page provides access to selected publications, patents and intellectual property, and videos and presentations so you can examine the research in greater detail.
These materials offer an introduction for pharmaceutical companies, universities and research institutions, medical institutions, diagnostics and medical device companies, and others considering co-development or technology licensing.
This page and its materials do not solicit the purchase of shares or other securities, investments, deposits, loans, or other funds from the general public.
Collaborative research, technology licensing, co-development, and business or equity partnerships will be discussed individually and pursued under due diligence and formal agreements where appropriate.
FEATURED DOCUMENTS
Public Materials
COMPANY & TECHNOLOGY OVERVIEW
Diabetes Cure Research & Cell-Targeting Technology
Biozipcode™ Company Overview
This overview introduces the research and technology of Biozipcode, Inc.
It covers research into abnormal hematopoietic stem cells and bone marrow-derived cells that treats diabetes as more than a blood glucose disorder, as well as Biozipcode™ cell-targeting technology for recognizing particular cells and tissues.
It also outlines potential applications beyond diabetes, including cancer, diagnostics and biomarkers, DDS, and tissue regeneration.
Contents
Diabetes stem cell research / research toward complete diabetes remission / Biozipcode™ / in vivo biopanning / cell targeting / cancer targeting / R&D pipeline / academic collaboration / intellectual property
5-ALA RESEARCH
About 5-ALA
Clinical Research & Research Potential
This document summarizes published research on 5-ALA (5-aminolevulinic acid) in relation to heme synthesis, mitochondria, energy metabolism, and glucose metabolism.
Biozipcode, Inc. considers 5-ALA a research candidate in diabetes and metabolic disease, not an established treatment for complete diabetes remission.
Please use it as background on existing human research and its relationship to our diabetes research.
RESEARCH EVIDENCE
Explore the Research Evidence
Our research achievements pages provide more detail on the scientific evidence and intellectual property behind our R&D, beyond the PDF materials.
Read them alongside the documents to follow the path from research hypothesis → scientific evidence → intellectual property → current pipeline.
SELECTED PUBLICATIONS
Selected Publications
Explore representative papers underpinning current diabetes stem cell research and Biozipcode™ cell-targeting technology.
They include research on pancreatic islet neogenesis from 2003; CD106-positive short-term hematopoietic stem cells and diabetic neuropathy from 2021; complete remission in mice with STZ-induced diabetes from 2023; and a 2026 human study examining peripheral blood CD34-positive subsets in type 2 diabetes as a candidate cellular biomarker. The page also covers studies of dorsal root ganglia (DRG), spinal cord, microglia, and cancer targeting related to Biozipcode™.
PATENTS & INTELLECTUAL PROPERTY
Patents & Intellectual Property
Explore intellectual property intended to advance research findings in diabetes therapies, abnormal stem cells, diagnostics and detection, and HDAC modulation toward therapeutic and diagnostic technologies.
The public page describes major international application families including PCT/JP2020/039044, PCT/JP2020/039045, PCT/JP2022/008036, and PCT/JP2022/040140, along with an IP strategy for Biozipcode™ combining targeting peptide sequences, uses, payload combinations, DDS, analyses, and know-how.
VIDEOS & PRESENTATIONS
Videos, Lectures & Presentations
Explore videos, conference presentations, lectures, seminars, and media coverage on diabetes stem cells, research toward complete remission, Biozipcode™, and cell targeting.
The collection includes specialist research presentations and accessible introductions to the background of the work.
BIOZIPCODE™ RESEARCH
Explore Biozipcode™ in More Detail
Biozipcode™ is a cell-targeting technology that seeks short peptides recognizing particular cells and tissues for potential diagnostic and therapeutic applications.
It combines phage display, in vivo biopanning, NGS, and bioinformatics to discover candidate sequences recognizing target cells and tissues.
For more technical background, visit our research and technology pages and the research information of Kyoto University’s Department of Biocommunication Development.
DEVELOPMENT PIPELINE
Where Is the Research Heading Now?
Academic papers and patents document past research.
Biozipcode, Inc. is also connecting those findings to its current R&D pipeline.
Our principal programs include:
- investigational diabetes remission therapy
- diabetes stem cell biomarkers
- investigational Biozipcode™ diabetes cell-targeted therapy
- investigational cancer cell-targeted therapy
- cell-targeted tissue regeneration
Our R&D focuses on these programs.
Each pipeline page distinguishes the scientific evidence available today from the human validation, product development, and nonclinical or clinical work still needed.
FOR PARTNERS
Information for Your Area of Interest
CONFIDENTIAL MATERIALS
About Confidential Research & Business Materials
Biozipcode, Inc. also holds detailed information needed for collaborative research, technology evaluation, and co-development beyond its public materials.
This may include detailed research data, unpublished results, candidate sequences and technical information, IP strategy, product development plans, Target Product Profiles, and nonclinical, CMC, or clinical development plans.
Because these materials may contain confidential information, we do not make them available for public download.
If you are considering a specific research collaboration, license, or co-development project, we can share materials relevant to the proposed work under an NDA where appropriate.
Explore the research in public materials.
Review the evidence on our detailed pages.
Assess specific technology and development information under an NDA.
We follow this staged approach to sharing information.
For Partners
Building on diabetes stem cell research and Biozipcode™ cell-targeting technology, we are advancing new diagnostic and therapeutic technologies for difficult-to-treat diseases.
We work with pharmaceutical companies and research institutions to advance research, development, and practical applications based on diabetes stem cell research, Biozipcode™, and related research platforms.
We conduct collaborative research with universities, research institutions, medical institutions, and companies in fields including diabetes, cancer, regenerative medicine, biomarkers, and drug delivery systems (DDS).
We are exploring technology licensing for research findings involving diabetes treatment and diagnosis, abnormal stem cells, HDAC-related technologies, and Biozipcode™.
A cell-targeting platform that identifies short peptide sequences recognizing specific cells and tissues for potential diagnostic and drug delivery applications.
We are considering strategic investment and equity partnerships that offer business synergies and support research, development, and practical applications over the medium to long term.
Access materials on Biozipcode, Inc., its research and technologies, pipeline, research collaborations, licensing, and related topics.
